The WNT/β-catenin pathway was stimulated with mouse Recombinant WNT3a (Peprotech, NJ, USA) at a final concentration of 100 ng/ml. β-catenin transcriptional activity was inhibited by treating cells with iCRT14 (Santa Cruz, CA, USA) at a final concentration of 10 μM. c-Met signalling was stimulated with recombinant human HGF (R&D Systems) at a final concentration of 75 nM, whilst it was inhibited with Capmatinib (Biozol Diagnostica, Eching, Germany) at a final concentration of 2 nM. c-Met and EGFR signalling were concomitantly stimulated with recombinant human EGF (Corning, NY, USA) at a final concentration of 20 nM. Downstream signalling was inhibited with Erlotinib at a final concentration of 5 μM. Recombinant WNT3a, HGF, and EGF were diluted in 0.1% BSA in PBS, which was therefore used as a control in all experiments and is indicated with the “unstimulated” label in respective figures. iCRT-14 and Capmatinib were diluted in DMSO, whilst Erlotinib was diluted in PBS. Thus, the respective vehicle controls (veh. ctrl) were used in the experiments.
Erlotinib
Manufactured by Corning
Sourced in United States
Erlotinib is a laboratory product manufactured by Corning. It is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib is used for research purposes in cell culture and in vitro studies.
Automatically generated - may contain errors
2 protocols using erlotinib
1
Modulating Signaling Pathways in Cells
2
Modulating WNT, c-Met, and EGFR Signaling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The WNT/β-catenin pathway was stimulated with mouse Recombinant WNT3a (Peprotech, NJ, USA) at a final concentration of 100 ng/ml. β-catenin transcriptional activity was inhibited by treating cells with iCRT14 (Santa Cruz, CA, USA) at a final concentration of 10 µM. c-Met signalling was stimulated with recombinant human HGF (R&D Systems) at a final concentration of 75 nM, whilst it was inhibited with Capmatinib (Biozol Diagnostica, Eching, Germany) at a final concentration of 2 nM. c-Met and EGFR signalling were concomitantly stimulated with recombinant human EGF (Corning, NY, USA) at a final concentration of 20 nM. Downstream signalling was inhibited with Erlotinib at a final concentration of 5 µM. Recombinant WNT3a, HGF, and EGF were diluted in 0.1% BSA in PBS, which was therefore used as a control in all experiments and is indicated with the "unstimulated" label in respective figures. iCRT-14 and Capmatinib were diluted in DMSO, whilst Erlotinib was diluted in PBS. Thus, the respective vehicle controls (veh. ctrl) were used in the experiments.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!